Novel β-lactamase/β-lactamase inhibitors have become critical drugs to combat the most resistant Gram-negative infections. A series of new compounds with even more broad and potent activity are in the horizon to add to the therapeutic armamentarium. Today, we will discuss these drugs with experts in the field.
Objectives:
• Review the BL/BLI combinations that are currently available in clinical practice
• Discuss future perspectives of BL/BLI armamentarium
• Provide insights into resistance developing for this class of antibiotics.
This episode of Editors in Conversation is brought to you by the Antimicrobial Agents and Chemotherapy Journal and hosted by AAC Editor in Chief, Cesar Arias.
AAC is available at asm.org/aac.
Follow Cesar on twitter at / superbugdoc for AAC updates.
Subscribe to the podcast at asm.org/eic
👍 Subscribe to ASM's KZread channel at goo.gl/mOVHlK
✅ Become a member today at asm.org/Membership
🔬 Learn more about the American Society for Microbiology at www.asm.org
📱 Join us on social:
Facebook: / asmfan
Twitter: / asmicrobiology
Instagram: / asmicrobiology